-- Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.
The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.
Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.
CNS Pharmaceuticals (CNSP) shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.
Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.
American Express Global Business Travel, which is operated by Global Business Travel Group (GBTG), said Monday it has entered into a definitive agreement to be acquired by Long Lake Management for $9.50 per share in an all-cash deal valued at about $6.3 billion.
Shares soared 57%, with intraday trading volume of over 61.6 million from a daily average of about 1.6 million.
Price: $146.00, Change: $+20.35, Percent Change: +16.20%